Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the closing of its previously announced underwritten public offering of 14,000,000 shares of newly issued common stock at a public offering price of $7.10 per share. The Company received …
Below, Benzinga looks at the best performing small-caps on the session. Allos Therapeutics (NASDAQ: ALTH) - This stock had some bizarre trading activity on Tuesday. At one point, shares plunged, before proceeding significantly higher …
American Express
Allos Therapeutics, Inc. (ALTH) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion and in honor of patients with blood cancers and their families, Dr. Charles Morris, Chief Medical Officer of …
These stories made today's top 10 list of articles and videos on TheStreet. Shares of Allos Therapeutics (Nasdaq:ALTH) were gapping down Friday morning with an open price 15.1% lower than Thursday's closing price. The stock closed at …
DALLAS, June 17, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring biopharmaceutical stock Allos Therapeutics Inc. (Nasdaq:ALTH). The report includes the most recent data from the …
When it comes time to scrub off what is invariably too much speed, the Alth rotors and Vesrah pads proved to be a great combination. Overall braking power is considerably stronger than stock, with better initial bite and progression, even …
Machine Project
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 ... Article printed from InvestorPlace Media, http://investorplace.com/2012/09/6-biotechnology-stocks-to-buy-now-alny-dusa-grfs/.
Its less than perfect performance in phase two clinical trials dropped Spectrum stock by nearly a quarter ... On the up side, Spectrum announced it had acquired Allos Therapeutics (NASDAQ:ALTH) and its drug Folotyn. The drug is intended to …
Deeply
We see limited upside potential until Allos is successful in expanding its product portfolio. The stock carries a Zacks #3 Rank (Hold rating) in the short-run.